Alpha Cognition Inc ACOGF

Primary Symbol: C.ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

CSE:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by yopmemama021on Mar 04, 2022 12:52pm

70 Views

Post# 34483837

ACOG

$ACOGF

$ACOG.V @ $0.99 , mc $60.88M

Excited to have eyes on $ACOG at these levels while still in clinical trials

Potential for some major movement Once their revolutionary treatment is FDA approved

Lots of success and positive news coming from trials so far :

The ALPHA-1062 Traumatic Brain Injury treatment is proving to be beneficial to both brain structure(neurogenesis) and function( improvement in motor/sensory/ cognition performance )

Looking forward to more updates on their progress.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle